NEWDIGS

NEW Drug Development ParadIGmS

An initiative to transform the drug development process within the context of an evolving global healthcare marketplace.

NEWDIGS was launched in spring 2009 to address a number of key change drivers surrounding drug development in the current marketplace including:

• Emerging science and technologies that have increased R&D costs but so far have  failed to demonstrate the anticipated return on investments
• A growing demand for more and better data on the benefits, risks, and relative effectiveness of drugs
• An ongoing need to improve the productivity and efficiency of the innovation process
• Reforms that are changing the policy and economic environment associated with healthcare in the U.S.
• Globalization that is bringing new challenges and opportunities to the healthcare industry

NEWDIGS applies a holistic engineering systems methodology to structure the redesign process, and to measure the impact of new elements.  This “Enterprise Transformation” methodology is rooted in value creation for all key stakeholders as a critical driver of large scale, sustainable change.

Additional information

• Background: “Drug Safety Futures 2020” (PDF)
• Summary of Launch Meeting (May 2009) (PDF)
• More on Enterprise Transformation from MIT’s Lean Advancement Initiative

Sponsors and Collaborators:

CBI greatly appreciates the active participation of the following organizations in the strategic assessment and planning phase of NEWDIGS:

• Aetna
• Bayer Healthcare
• Brookings Institution
• Centers for Disease Control and Prevention (CDC)
• Eli Lilly and Company
• U.S. Food and Drug Administration (FDA)
• Johnson & Johnson
• Medco Health Solutions Inc.
• Pfizer Inc.
• Quintiles Transnational Corp.
• Vertex Pharmaceuticals Inc.
• WellPoint Inc.